Market Place
Sourcing Support
NMD670 Gains FDA Orphan Drug Designation For Charcot-Marie-Tooth
06 Jan 2025 //
GLOBENEWSWIRE
NMD Pharma Publishes Phase 1 Data of NMD670 in Healthy Volunteers
19 Dec 2024 //
GLOBENEWSWIRE
NMD Pharma Publishes ClC-1 Inhibition Data for Charcot-Marie-Tooth
18 Dec 2024 //
GLOBENEWSWIRE
NMD Pharma Initiates Ph 2 Study of NMD670 in Charcot-Marie-Tooth
18 Nov 2024 //
GLOBENEWSWIRE
NMD Pharma Initiates Phase 2 Study Of NMD670 In Charcot-Marie-Tooth
18 Nov 2024 //
GLOBENEWSWIRE
NMD Pharma To Present Data On Therapy At AANEM Annual
11 Oct 2024 //
GLOBENEWSWIRE
NMD Pharma To Present Data of Muscle Therapy At AANEM Annual Meeting
11 Oct 2024 //
GLOBENEWSWIRE
NMD Pharma Adds Senior Recruits To Support Growing Pipeline
11 Jul 2024 //
GLOBENEWSWIRE
NMD Receives IND Clearance For Phase 2 Trial Of NMD670 In Charcot-Marie-Tooth
18 Jun 2024 //
GLOBENEWSWIRE
NMD Pharma Initiates Phase 2b Trial of NMD670 in GMG Patients
11 Jun 2024 //
GLOBENEWSWIRE
NMD Pharma Receives FDA IND Clearance to initiate a Ph2b Trial of NMD670
22 Mar 2024 //
GLOBENEWSWIRE
NMD Publishes Comprehensive Data Package for NMD670 in Science
21 Mar 2024 //
GLOBENEWSWIRE
NMD Pharma announces presentations on skeletal muscle targeted ClC-1 therapy
01 Mar 2024 //
GLOBENEWSWIRE
NMD Pharma Appoints Morten Bull as SVP
22 Jan 2024 //
GLOBENEWSWIRE
NMD Pharma Raises ‚¬75 Million (~$80 million) in a Series B Financing
15 Nov 2023 //
GLOBENEWSWIRE
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial
03 Oct 2023 //
GLOBENEWSWIRE
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial
02 Oct 2023 //
GLOBENEWSWIRE
NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy
26 Sep 2023 //
GLOBENEWSWIRE
NMD Pharma to host a Satellite Symposium
08 Sep 2023 //
GLOBENEWSWIRE
NMD Reports Results from ESTABLISH Study “ an International Observational Study
20 Jun 2023 //
GLOBENEWSWIRE
NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy
01 Jun 2023 //
GLOBENEWSWIRE
NMD Pharma initiates Phase I trial of NMD1343 in healthy subjects
24 May 2023 //
CLINICAL TRIALS ARENA
NMD Pharma initiates Phase I safety study of NMD1343
23 May 2023 //
GLOBENEWSWIRE
NMD Pharma initiates Phase I study of NMD1343
23 May 2023 //
GLOBENEWSWIRE
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors
03 Jan 2023 //
GLOBENEWSWIRE
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors
03 Jan 2023 //
GLOBENEWSWIRE
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670
14 Dec 2022 //
GLOBENEWSWIRE
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670
14 Dec 2022 //
GLOBENEWSWIRE
Chasing Big Pharma rivals, NMD posts data on rare disease drug
11 Oct 2022 //
FIERCEBIOTECH
Novo Seeds Portfolio Company NMD Reports Positive Top-Line Phase I/IIa Data
11 Oct 2022 //
PHARMIWEB
NMD Pharma Reports Positive Top-Line Data from a Ph I/IIa Trial of NMD670
10 Oct 2022 //
GLOBENEWSWIRE
NMD Pharma receives Orphan Drug Designation from FDA for NMD670
27 Sep 2022 //
GLOBENEWSWIRE
NMD Pharma appoints Dr. Jorge A. Quiroz as EVP, Chief Medical Officer
10 May 2022 //
GLOBENEWSWIRE
NMD Pharma expands its US presence
03 May 2022 //
GLOBENEWSWIRE
NMD Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease
08 Jul 2021 //
GLOBENEWSWIRE
NMD Pharma Doses the First Myasthenia Gravis Patient with NMD670
30 Jun 2021 //
GLOBENEWSWIRE
